ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3036% below fair value
$13.68+0.44 (+3.32%)
Close on Nov 13, 2026Market cap $3.06BP/E 17.8Yield –
ADMA Biologics total assets
Total assets on the balance sheet at the end of each period.
ADMA Biologics's total assets was $732.49M at Sep 30, 2026. For fiscal 2025 it was $624.24M, up 27.7% from the year before. Over ten years it grew 38.7% a year on average. The highest annual figure on record is $624.24M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $624.24M | +27.7% |
| FY2024 | Dec 31, 2024 | $488.68M | +48.5% |
| FY2023 | Dec 31, 2023 | $329.18M | -5.5% |
| FY2022 | Dec 31, 2022 | $348.46M | +26.1% |
| FY2021 | Dec 31, 2021 | $276.25M | +33.0% |
| FY2020 | Dec 31, 2020 | $207.67M | +63.4% |
| FY2019 | Dec 31, 2019 | $127.09M | +43.0% |
| FY2018 | Dec 31, 2018 | $88.88M | -17.7% |
| FY2017 | Dec 31, 2017 | $108.02M | +356.1% |
| FY2016 | Dec 31, 2016 | $23.69M | -0.1% |
| FY2015 | Dec 31, 2015 | $23.71M | -12.2% |
| FY2014 | Dec 31, 2014 | $27.02M | -15.5% |
| FY2013 | Dec 31, 2013 | $31.98M | +105.6% |
| FY2012 | Dec 31, 2012 | $15.56M | +431.6% |
| FY2011 | Dec 31, 2011 | $2.93M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $732.49M | +28.8% |
| Q2 FY2026 | Jun 30, 2026 | $684.21M | +22.5% |
| Q1 FY2026 | Mar 31, 2026 | $665.18M | +30.3% |
| Q4 FY2025 | Dec 31, 2025 | $624.24M | +27.7% |
| Q3 FY2025 | Sep 30, 2025 | $568.69M | +45.6% |
| Q2 FY2025 | Jun 30, 2025 | $558.38M | +48.3% |
| Q1 FY2025 | Mar 31, 2025 | $510.57M | +45.5% |
| Q4 FY2024 | Dec 31, 2024 | $488.68M | +48.5% |
| Q3 FY2024 | Sep 30, 2024 | $390.62M | +11.9% |
| Q2 FY2024 | Jun 30, 2024 | $376.40M | +9.7% |
| Q1 FY2024 | Mar 31, 2024 | $350.88M | +3.0% |
| Q4 FY2023 | Dec 31, 2023 | $329.18M | -5.5% |
| Q3 FY2023 | Sep 30, 2023 | $349.00M | +16.1% |
| Q2 FY2023 | Jun 30, 2023 | $343.03M | +15.5% |
| Q1 FY2023 | Mar 31, 2023 | $340.79M | +10.6% |
| Q4 FY2022 | Dec 31, 2022 | $348.46M | +26.1% |
| Q3 FY2022 | Sep 30, 2022 | $300.56M | +25.9% |
| Q2 FY2022 | Jun 30, 2022 | $296.93M | +27.5% |
| Q1 FY2022 | Mar 31, 2022 | $308.03M | +30.7% |
| Q4 FY2021 | Dec 31, 2021 | $276.25M | +33.0% |
| Q3 FY2021 | Sep 30, 2021 | $238.64M | +25.6% |
| Q2 FY2021 | Jun 30, 2021 | $232.81M | +21.5% |
| Q1 FY2021 | Mar 31, 2021 | $235.67M | +11.9% |
| Q4 FY2020 | Dec 31, 2020 | $207.67M | +63.4% |
| Q3 FY2020 | Sep 30, 2020 | $189.98M | +37.9% |
| Q2 FY2020 | Jun 30, 2020 | $191.54M | +33.7% |
| Q1 FY2020 | Mar 31, 2020 | $210.52M | +169.5% |
| Q4 FY2019 | Dec 31, 2019 | $127.09M | +43.0% |
| Q3 FY2019 | Sep 30, 2019 | $137.78M | +29.6% |
| Q2 FY2019 | Jun 30, 2019 | $143.27M | +21.7% |
| Q1 FY2019 | Mar 31, 2019 | $78.12M | -14.3% |
| Q4 FY2018 | Dec 31, 2018 | $88.88M | -17.7% |
| Q3 FY2018 | Sep 30, 2018 | $106.35M | +46.1% |
| Q2 FY2018 | Jun 30, 2018 | $117.75M | +39.1% |
| Q1 FY2018 | Mar 31, 2018 | $91.14M | +418.0% |
| Q4 FY2017 | Dec 31, 2017 | $108.02M | +356.1% |
| Q3 FY2017 | Sep 30, 2017 | $72.81M | – |
| Q2 FY2017 | Jun 30, 2017 | $84.64M | – |
| Q1 FY2017 | Mar 31, 2017 | $17.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $23.69M | – |
See a number that looks wrong?